Plexus Vaccine Inc.
This article was originally published in Start Up
Plexus Vaccine Inc. is a genomics-driven vaccine development company with a platform based on computational drug discovery and immunological informatics. In the near term, it is using its expertise in B-cell-based vaccines to design novel vaccines against potential biowarfare agents Yersinia pestis (plague) and anthrax, but the company believes that its platform is expandable to broad potential uses.
You may also be interested in...
Computational drug discovery companies promise to unite data from many of the disparate steps pharmaceutical companies go through these days, to enable more efficient lead identification, optimization, and testing.
CombinatoRx's platform screens combinations of known drugs to find pairs that could deliver a one-two punch to diseases such as cancer and rheumatoid arthritis.
Paths to commercialization are uncertain in nutrigenomics, an emerging science which seeks to identify gene-food interactions that differ among subpopulations and between individuals and to personalize diets to prevent disease.